Title : Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.

Pub. Date : 2012 Feb 15

PMID : 22173548






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The activity of selumetinib and vorinostat against the KRAS-mutant SW620 and SW480 CRC cell lines was studied in vitro and in vivo. AZD 6244 KRAS proto-oncogene, GTPase Homo sapiens
2 CONCLUSION: These data indicate that the rationally based combination of the mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor, selumetinib, with the HDAC inhibitor vorinostat results in synergistic antiproliferative activity against KRAS-mutant CRC cell lines in vitro. AZD 6244 KRAS proto-oncogene, GTPase Homo sapiens